Description
Respiratory inhalers are the devices which are used to control the respiratory conditions by directly inhaling the drug into the respiratory tract. Respiratory inhalers are used to assist a patient encountering breathing problems resulting from respiratory disorders such as fibrosis, asthma, COPD and ARDS and others.
The global respiratory inhalers market is expected to reach USD 33,572.9 Million by 2023 at a CAGR of 6.1% during the forecast period.
Globally, on the basis of type, manually operated inhalers account for the largest market share of 89.9%, of the market in 2016. The massive share is majorly attributed to the widespread availability and use of the conventional inhaler devices and the lack of awareness and the lesser availability of the digital and smart inhaler devices in all parts of the world. However, the market is changing and Digital inhalers & smart inhaler segment will show a rapid growth globally after 2018.
Globally, On the basis of application, COPD will be the fastest growing application segment growing at a CAGR of 6.5% from 2017 to 2023, as the number of COPD patients is on the rise and patients need a concrete treatment method to counter the disease. Moreover, many awareness programs and campaigns have been started in the last few years in the developing regions such as Asia-Pacific and Middle East & Africa.
Dry Powder Inhalers segment accounted for the largest market share of North America respiratory inhalers market, by product, registering revenue of USD 3,969.6 million in 2016 and expected to reach USD 6,421.0 million by 2023. In North America, metered dose inhalers is the fastest growing segment, and is expected to grow at the CAGR of 6.7% during forecasted period. Dry Powder Inhaler segment being available widespread dominated the market in most of the countries such as US, Germany, France, UK, India, China, Australia, Middle East, and Republic of Korea among others. Apart from these two,
North America commands largest market share of 35.1%, minting USD 7,237.8 million in 2016. European market is second largest after North America with 33.3% market share. Globally, Asia-Pacific region is one of the fastest growing markets for Respiratory Inhalers. It was valued at USD 4,628.5 million in 2016, and is expected to reach USD 7,841.3 million by 2023, at the rate of 6.7% during the forecast period.
Key Players
The leading market players in the global respiratory inhalers market include Adherium Limited, AstraZeneca PLC, Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., GlaxoSmithKline PLC, Propeller Health, and Teva Pharmaceutical Industries Ltd.
Study objectives of Respiratory Inhalers market
Ø To provide insights about factors influencing and affecting the market growth
Ø To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
Ø To provide historical and forecast revenue of the market segments based on types, products, applications, end users, and its sub-segments.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
Target Audience
• Medical devices manufacturers
• Medical devices distributors
• Pharmaceutical companies
• Hospitals & Clinics
• Potential investors
• Key executive (CEO and COO) and strategy growth manager
Key Findings
• Metered Dose Inhalers will be the fastest growing product segment growing at a CAGR of 6.5% from 2017 to 2023
• COPD will be the fastest growing Application segment growing at a CAGR of 6.5% from 2017 to 2023
• North America held the largest market share of 35.1% in 2016, while Asia-Pacific is expected to register fastest growth of 6.7% CAGR during the forecast period.
• Asia-Pacific market is expected to reach by USD 7,841.3 million by 2023.
The reports also cover country level analysis:
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest Of Western Europe
• Eastern Europe
• Asia-Pacific
• Japan
• China
• India
• Republic of Korea
• Rest of Asia-Pacific
• Middle East & Africa
• Middle East
• Africa
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introducton
4.2 Drivers
4.2.1 Rising prevalence of chronic respiratory disease
4.2.2 Increasing usage of combination therapy
4.2.3 Growing need for rescue medication
4.2.4 Technological advancements
4.3 Restraints
4.3.1 No single, effective device for every respiratory disorders
4.3.2 Side effects and complications during inhalation
4.3.3 High price
4.3.4 Non-standardized dosage
4.4 Opportunities
4.4.1 Advanced products
4.4.2 Increasing demand in developing countries
4.5 Challenges
4.5.1 Strong competition
4.5.2 More advanced products
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6 Global Respiratory Inhalers Market, By Type
6.1 Introduction
6.2 Manually Operated Inhaler
6.3 Digitally Operated Inhaler
7 Global Respiratory Inhalers Market, By Product
7.1 Introduction
7.2 Dry Powder Inhaler
7.3 Metered Dose Inhaler
8 Global Respiratory Inhalers Market, By Application
8.1 Introduction
8.2 Asthma
8.3 COPD
9 Global Respiratory Inhalers Market, By End User
9.1 Introduction
9.2 Hospitals & Clinics
9.3 Respiratory Care Centers
10 Global Respiratory Inhalers Market, By Region
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Western Europe
10.3.7 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Republic of Korea
10.4.5 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Share Analysis
12 Company Profiles
12.1 Adherium
12.1.1 Company Overview
12.1.2 Product/Business Overview
12.1.3 Adherium Health: Financials
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 AstraZeneca
12.2.1 Company Overview
12.2.2 Product overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Boehringer Ingelheim GmbH
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Chiesi Farmaceutici S.p.A.
12.4.1 Company Overview
12.4.2 Product Overview
12.4.3 Financial Overview
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.5 GlaxoSmithKline
12.5.1 Company Overview
12.5.2 Product overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Propeller Health
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Propeller Health: Financials
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Teva Pharmaceutical Industries Ltd
12.7.1 Company Overview
12.7.2 Product Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
